Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias or Solid Tumors
Chronic Myeloproliferative Disorders / Posted 1 year ago
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to < 18 years with advanced leukemias, lymphomas, and solid tumors.
-
Inclusion Criteria :
- Ages Eligible for Study: 1 Year to 17 Years (Child)
- Sexes Eligible for Study: All
- Accepts Healthy Volunteers: No
- Histologically or cytologically confirmed diagnosis of the following malignancies: CP-CML, blast phase chronic myeloid leukemia (BP-CML), accelerated phase chronic myeloid leukemia (AP-CML); acute lymphoblastic leukemia/acute lymphocytic leukemia (ALL); acute myeloid leukemia (AML); other leukemias; lymphoma; any other tumors, including tumors of the central nervous system (CNS), for which standard therapy is not available or is not indicated
- Phase 1:
- Participants with CML who are resistant to or intolerant to at least 1 prior BCR-ABL-targeted TKI therapy.
- Participants with solid tumors (including tumors of the CNS) or lymphomas who have progressed despite standard therapy or for whom no effective standard therapy is available or indicated.
- Phase 2 (CP-CML): Participants who are resistant to or intolerant of at least 1 prior BCR-ABL-targeted TKI therapy.
- Phase 2 (other leukemias or solid tumors):
- * Participants with ALL who have all available or indicated therapies, which must have included 1 prior BCR-ABL-targeted TKI therapy.
- Participants with solid tumors (including tumors of the CNS) with mutations where ponatinib may have biological activity or lymphomas who progressed despite standard therapy or for whom no effective standard therapy is available or indicated.
- Karnofsky performance status
- Must have recovered to &lt; Grade 2 per the NCI CTCAE v5.0 or to baseline from any non-hematologic toxicities (except alopecia) due to previous therapy.
- Willingness to avoid pregnancy or fathering children.
-
Exclusion Criteria :
- Prior therapies:
- Participants with BP-CML, ALL, or AML who have received corticosteroids or hydroxyurea within 24 hours before the first dose of ponatinib; vincristine within 7 days before the first dose of ponatinib; or other chemotherapy (excluding intrathecal chemotherapy) within 14 days before the first dose of ponatinib
- Participants (except the BP-CML, ALL, and AML participants described above) who have had cytotoxic chemotherapy or radiotherapy within 21 days (or 42 days for nitrosoureas or mitomycin C) before the first dose of ponatinib.
- Autologous or allogeneic stem cell transplant <3 months before the first dose of ponatinib.
- Prior treatment with any of the following: immunosuppressive therapy (including post stem cell transplant regimens) within 14 days before the first dose of ponatinib; any targeted cancer therapy (including TKIs) within 7 days before the first dose of ponatinib; any other investigational anticancer agents within 30 days or 5 half-lives, whichever is longer, before randomization; any monoclonal antibody-directed anticancer therapy within 5 half-lives of the first dose of ponatinib; any chimeric antigen receptor therapy within 28 days before the first dose of ponatinib; ponatinib.
- Laboratory values at screening outside the protocol-defined ranges.
- Significant concurrent, uncontrolled medical condition, including but not limited to protocol-defined pancreatic, cardiac, cerebral, coagulation, gastrointestinal, and genetic conditions.
- Any active ≥ Grade 2 graft-versus-host disease.
- Chronic or current active uncontrolled infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment.
- Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection that requires treatment or at risk for HBV reactivation.
- Known HIV infection.
- Known hypersensitivity or severe reaction to ponatinib or excipients of ponatinib.
- Receipt of live (including attenuated) vaccines or anticipation of need for such vaccines during the study.
- Females who are pregnant or lactating.
- Study start date : January 29, 2020
- Study end date : November 5, 2024
- Wales-Based Study Contact : Please speak to your clinician
- Principal Investigator : Mohammed-El-Amine Bensmaine, MD (Incyte Biosciences International Sàrl)